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The ESC has published a series of guidelines on heart failure (HF) over the last 25 years, 
most recently in 2016.  Given the amount of new information that has become available since 
then, the HFA of the ESC recognized the need to review and summarise recent 
developments in a consensus document.  Here we report from the HFA workshop that was 
held in January 2019 in Frankfurt.  This expert consensus report is neither a guideline update 
nor a position statement, but rather a summary and consensus view in the form of consensus 
recommendations.  The report describes how these guidance statements are supported by 
evidence, it makes some practical comments, and it highlights new research areas and how 
progress there might change the clinical management of HF.  We have avoided re-
interpretation of information already considered in the 2016 ESC/HFA guidelines. 
Specific new recommendations have been made based on the evidence from major trials 
published since 2016, including SGLT2 inhibitors in type 2 diabetes mellitus; MitraClip for 
functional mitral regurgitation; atrial fibrillation ablation in HF; tafamidis in cardiac 
transthyretin amyloidosis; rivaroxaban in HF; ICD’s in non-ischaemic HF; and telemedicine 
for HF.  In addition, new trial evidence from smaller trials and updated meta-analyses have 
given us the chance to provide refined recommendations in selected other areas.  
Further, new trial evidence is due in many of these areas and others over the next two years, 
in time for the planned 2021 ESC guidelines on the diagnosis and treatment of acute and 
chronic heart failure.  












The ESC has published a series of guidelines on heart failure (HF) over the last 25 years, 
most recently in 2016123456. The next ESC guideline is not due until 2021. Given the amount 
of new information that has become available since 2016, the HFA of the ESC recognized 
the need to review and summarise recent developments in a consensus document. The 
growing appreciation that HF is caused by a great diversity of aetiologies, with various 
phenotypes and co-morbidities that affect the response to and, therefore, the choice of 
therapy creates exciting new opportunities to improve overall and personalised care, to the 
individual patient7.  
This document is a report from the HFA workshop that was held in January 2019 in 
Frankfurt. The meeting brought together an international group of experts on HF to discuss 
and evaluate new evidence published after finalisation of the 2016 ESC Guidelines for the 
diagnosis and treatment of AHF and CHF that occurred in March 2016 prior to its publication 
in May 2016.8  There was no industry support for the meeting or any aspect of the consensus 
report, and there was no industry representation at the meeting.  This expert consensus 
report is neither a guideline update nor a position statement, but rather a summary and 
consensus view in the form of consensus recommendations (see also Supplementary Tables 
1 and 2).  The consensus report uses standard recommendation language to make our 
opinions understood in context and using comparable language, but it refrains from providing 
formal (numbered) recommendation classes or evidence levels.  In general, the process 
followed was that the leadership group reviewed the covered field and assessed any new 
evidence that had been peer-review published since 2016.  We opened this to all participants 
at the meeting and by email, and we agreed by consensus which fields were eligible for new 
statements via an iterative process to reach eventual consensus on all issues.  No voting 
was required.  The report describes how these guidance statements are supported by 
evidence, it makes some practical comments, and it highlights new research areas and how 











progress there might change the clinical management of HF. We have avoided re-
interpretation of information already considered in the 2016 ESC/HFA guidelines.  
 
A – PHARMACOTHERAPY 
 
1.  SGLT2 inhibitors 
Consensus recommendation.  
- The 2016 Guideline indicated that empagliflozin should be considered in patients with 
T2DM “in order to prevent or delay the onset of heart failure or prolong life”8.  
- The 2019 expert consensus was that canagliflozin and dapagliflozin should also be 
considered for patients with T2DM and either established CV disease or at high CV risk in 
order to prevent or delay the onset of and hospitalisations for HF.  
- At this stage, no specific recommendations for the use of SGLT2 inhibitors in patients with 
established HF can be made. 
Supporting evidence. Empagliflozin was compared to placebo in the EMPA-REG 
OUTCOME trial in patients with T2DM and established CV disease. Patients assigned to 
empagliflozin had a 30% reduction in all-cause mortality, a 38% reduction in CV mortality, 
and a 35% reduction in HF hospitalizations9. Thereafter, similar findings were reported with 
regards to reductions in HF hospitalisations for dapagliflozin10 in the DECLARE-TIMI 58 
study and for canagliflozin11 in the CANVAS programme, that included T2DM with 
established CV disease or increased CV risk, respectively, but not for all-cause mortality (HR 
0.90 and 0.93, respectively) or CV mortality (HR 0.96 and 0.93, respectively). Of note, in 
none of these trials was the presence of HF at baseline well characterised or phenotyped, so 
that any recommendation with regard to treating established HF and T2DM will be 
necessarily cautious.  











Most recently in the CREDENCE trial12, which enrolled patients at high risk of CV disease 
and mild to moderate CKD, canagliflozin reduced HF hospitalization by 39% (p<0.001) and 
CV death by 22% (p=0.05). All of these trials required patients to have T2DM, but fewer than 
15% had HF at baseline. Inclusion criteria and endpoints varied.  Positive results for SGLT2 
inhibitors regarding renal protection effects were also reported from the EMPA-REG 
OUTCOME trial with empagliflozin13 and the DECLARE-TIMI 58 study with canagliflozin11. 
The consensus view was that there is sufficient evidence to consider that the ability of 
SGLT2 inhibitors to prevent the hospitalisations for HF in patients with T2DM is a class 
effect. There is insufficient evidence to extend this observation to reductions in either CV or 
all-cause mortality or to patients without T2DM. Further clarification on whether the reduction 
in HF hospitalization occurs both in patients with and without pre-existing HF is required. One 
report from the CANVAS programme suggests, that the reduction in hospitalisations for HF 
was observed only for patients with pre-existing HF.14  
Subgroup analyses on the primary endpoints of the above mentioned trials have generally 
found similar relative benefit for patients with and without pre-existing HF, suggesting that the 
absolute benefit in patients with HF may be greater due to their high baseline risk. However, 
the diagnosis and phenotype of HF have generally not been well characterised. Of 10,142 
participants in the CANVAS programme, 14.4% had a history of HF and these patients 
experienced a greater reduction of CV death or HF hospitalization (HR 0.61, 95% CI 0.46-
0.80) compared to those without a history of HF at baseline (HR, 0.87; 95% CI, 0.72-1.06).15. 
Similar data were reported from the EMPA-REG Outcome trial where 706 patients (10.1%) 
were reported to have HF at baseline. But as in CANVAS, LVEF, NYHA class or levels of 
natriuretic peptides are not known16. In a post-hoc analysis of DECLARE-TIMI 58, benefits 
were greater in patients who were classified as HFrEF compared to patients classified as 
HFpEF, but measurement of LVEF was missing in 25% of patients.17 











Clinical trials in HF patients with and without T2DM and with HFrEF or HFpEF are ongoing 
(Table 3). These trials have recruited thousands of patients and have not yet been stopped 
for benefit or harm by their data-monitoring committees.  
Practical comments. SGLT2 inhibitors are already used for the management of T2DM. After 
initiating an SGLT2 inhibitor, on average, eGFR will deteriorate by 3-5 mL/min, but the long-
term rate of decline in eGFR is slowed13. These observations await confirmation in the setting 
of HF.  
SGLT2 inhibitors may interact with the effects of loop diuretic agents. Adjustment of the 
doses of diuretic agents and/or SGLT2 inhibitors may be required. Temporary withdrawal of 
SGLT2 inhibitors and diuretics and administration of fluids and sodium may be necessary for 
patients with clinical hypovolaemia or ketoacidosis.  Genital infection in the context of 
treatment with SGLT2 inhibitors can be prevented by better hygiene, and patients should be 
made aware of the risk of this complication. 
Directions for future development. In T2DM, new onset HF is common and is associated 
with a high mortality. Further subgroup analyses of existing trials should be conducted to 
confirm that SGLT2 inhibitors do indeed prevent new-onset of HF for patients who did not 
have HF at baseline. The results of clinical trials of patients with prevalent and well defined 
HFrEF and HFpEF (with and without T2DM being present at baseline) are awaited before 
recommending these agents for the management of HF itself, rather than only for the 
treatment of T2DM (Table 1).  
 
2.  Canakinumab 
Consensus recommendation. Evidence is not sufficient to provide a recommendation for 
its use in patients with HF. 











Supporting evidence. The CANTOS trial18 randomized 10,061 patients with prior 
myocardial infarction and elevated C-reactive protein to canakinumab or placebo. During a 
median follow-up of 3.7 years, 385 patients were hospitalized due to HF. Canakinumab use 
was associated with a dose-dependent reduction of hospitalization for HF and of the 
composite of hospitalization for HF or HF related mortality. A similar effect was observed in a 
subgroup of 2,173 patients (21.6%) with HF18,19. The consensus group considers the results 
on HF as hypothesis generating.  
Practical comments. In CANTOS, canakinumab was given as a subcutaneous injection 
ensuring high adherence. The substantial annual cost and lack of major benefit limit its use.  
Directions for future development. The FDA denied regulatory approval for canakinumab 
for patients with coronary artery disease20. A new potential therapeutic area is lung and 
potentially other forms of cancer21. Relevant trials are ongoing. 
 
3.  Sacubitril/Valsartan 
Consensus recommendation.  
- Sacubitril/valsartan is recommended as a replacement for ACE-I/ARBs to reduce the risk 
of HF hospitalization and death in ambulatory patients with HFrEF who remain symptomatic 
despite optimal medical treatment with an ACE-I, a beta-blocker and a MRA.  
- Initiation of sacubitril/valsartan rather than an ACE-I or an ARB may be considered for 
patients hospitalised with new-onset HF or decompensated CHF to reduce the short-term 
risk of adverse events and to simplify management (by avoiding the need to titrate ACE-I first 
and then switch to sacubitril/valsartan). Because these patients are already at high risk of 
events, there is no need to check plasma concentrations of natriuretic peptides prior to 
initiating sacubitril/valsartan. As indicated in the 2016 HF guidelines8, ambulatory patients 











with HFrEF should have an elevated plasma concentration of natriuretic peptides indicating 
increased risk and the need for more effective therapy. 
Supporting evidence. In secondary analyses of PARADIGM-HF, sacubitril/valsartan has 
been shown to improve survival in a broad range of patients who fulfilled the trial’s 
inclusion/exclusion criteria, including those aged 75 years and over, and/or with co-
morbidities such as T2DM.22,23,24 Compared with enalapril, administration of 
sacubitril/valsartan reduced the incidence of diabetes requiring insulin treatment25, and the 
incidence of hyperkalaemia in those on an MRA26.  The rate of decline in eGFR was also 
found lower with sacubitril/valsartan27, but this is not yet supported by “slope of decline” 
analyses.  Hypotension occurs more commonly with sacubitril/valsartan than with enalapril. 
However, patients who develop hypotension still appear to benefit from sacubitril/valsartan28. 
In the PIONEER-HF trial, patients with HFrEF hospitalized for new-onset (about one third) or 
worsening CHF (about two thirds) were stabilized and then randomly assigned to receive 
either sacubitril/valsartan or enalapril; the reduction in NT-proBNP was greater in those 
assigned to sacubitril/valsartan group at weeks 4 and 8 (the primary endpoint of this 
biomarker study)29. The rates of worsening renal function, hyperkalaemia, symptomatic 
hypotension and angioedema were similar in the two groups29 but there were fewer HF 
related adverse events in patients assigned to sacubitril/valsartan.  
In the open-label TRANSITION trial30, more than 1,000 patients with HFrEF hospitalized for 
worsening HF were randomized to start sacubitril/valsartan either before (initiated ≥24 h after 
haemodynamic stabilization) or after discharge (initiated within 14 days after discharge). 
Safety outcomes were similar for each strategy, indicating no disadvantage to early initiation, 
which may simplify management from both a clinician and patient perspective. A meaningful 
proportion of patients, 53% in PIONEER-HF and 24% in TRANSITION, respectively, were 
ACE-I/ARB naïve prior to sacubitril/valsartan initiation suggesting that the drug has similar 
efficacy and safety in these patients. 











Practical comments. Sacubitril/valsartan is safe and effective in a broad spectrum of 
patients with HFrEF.22,31,32,33,34,35 36, Its safety is similar in ACE-I/ARB naïve patients and thus 
its initiation may be considered also in these patients. In PIONEER29, the incidence of 
hyperkalaemia (≥5.5 mmol/L) was similar for those assigned enalapril (9.3%) or 
sacubitril/valsartan (11.6%). Amongst patients receiving MRA in the PARADIGM-HF trial, 
sacubitril/valsartan reduced the risk of severe hyperkalaemia (>6.0mmol/L) as compared with 
enalapril (3.1 vs 2.2 per 100 patient-years; HR, 1.37; P = .02)37. Sacubitril/valsartan may slow 
the rate of decline in eGFR and, in patients with T2DM, improve glycaemic control38.  
PIONEER-HF required patients to have and NT-proBNP >1,600pg/mL (BNP >400pg/mL). 
However, if the diagnosis of HF is certain and the patients has severe enough 
decompensation to require hospital admission, plasma concentrations of natriuretic peptides 
will usually be elevated and therefore their measurement might not be necessary. This is a 
very different situation from patients with ambulatory CHF and mild symptoms, in whom the 
benefit of sacubitril/valsartan is uncertain, if plasma concentrations of natriuretic peptides are 
not elevated39.  
Directions for future development. The PIONEER trial provides limited evidence that it is 
safe to initiate sacubitril/valsartan in ACE-I naïve patients; more evidence would be very 
welcome. Further results from an extensive trial programme including HFpEF (PARAGON-
HF, NCT01920711) and patients with left ventricular dysfunction after myocardial infarction 
(PARADISE-MI, NCT02924727) may further extend the indications for sacubitril/valsartan. It 
would also be of interest to understand whether the use of potassium binders can reduce 
hyperkalemia and enable more patients to tolerate sacubitril/valsartan at all, or at a higher 
dose. 
 
4.  Potassium binders 











Consensus recommendation.  
- Patiromer and ZS-9 may be considered in patients with HF with or without CKD to 
manage hyperkalaemia. In selected patients these therapies may enable use of MRAs and 
other RAASi’s in more patients and at higher doses, but it is not known whether this will 
improve patient outcomes. 
- Patiromer and ZS-9 may be considered in selected patients with HF with or without CKD 
in order to enable up-titration of MRA while avoiding hyperkalaemia. 
Supporting evidence.  Hyperkalemia is an important reason for under-use of life-saving 
therapy with RAASi’s in HF, and it is particularly frequent in patients with more advanced 
kidney disease and T2DM.40 Besides PEARL-HF41, a phase-2 trial published in 2011, new 
evidence is available from trials of patients with CKD and hypertension that also included 
subgroups of HF patients. The subgroup analysis of the AMETHYST-DN trial42 included 105 
HF patients on RAASi. Per protocol, RAASi dose could not be down-titrated but patiromer 
could be up-titrated using a study-defined dosing algorithm. Patiromer was effective in 
maintaining normokalaemia and was well tolerated over 52 weeks of intervention. Findings 
were similar in groups with mild (K 5.0-5.5 mmol/L; all received spironolactone up to 50mg on 
top of RAASi) and moderate (K 5.5-6.0 mmol/L) hyperkalaemia at baseline. The ability of 
patiromer to enable spironolactone initiation and uptitration in patients with HF and CKD was 
studied in 63 normokalaemic (K 4.3-5.1 mmol/L) patients in an open label design43. Patients 
were up-titrated to spironolactone 50mg od and the patiromer dose was adjusted to maintain 
potassium within the range 3.5 – 5.5 mmmol/L which at week 8 was achieved in 90% of 
patients. Both studies followed potassium and renal function regularly and demonstrated that 
patiromer had a good safety profile. No new evidence is available for ZS-9 in the field of HF. 
Practical comments. Patiromer and ZS-9 are approved for clinical use in many European 
countries and the USA, but in others regulatory approval for local use is incomplete, and 
hence these drugs are not available everywhere.  











Directions for future development. Subgroup results for HF patients enrolled in the 
AMBER trial are not yet available. A smaller trial of ZS-9 in HF patients to enable RAASi 
therapy (n=280) has been initiated (PRIORITIZE HF, NCT03532009). A substantial clinical 
trial of patiromer (n >2,000) is underway investigating its effects on morbidity and mortality 
(DIAMOND, NCT03888066).  
 
5.  Treatment of congestion using diuretics  
Consensus recommendation. Evidence is not sufficient to provide new practical 
recommendations for the use of diuretics. 
Supporting evidence. No new evidence was published since 2016 for diuretic therapy. The 
ADVOR trial with acetazolamide is ongoing44.  
Practical comments. With no strong evidence at hand, most of the volume management 
recommendations are consensus based and must focus on individual patients in whom 
tailored therapy is necessary. An HFA position statement with emphasis on clinical 
management was recently published45.  
Directions for future development. There are several trials ongoing, including ADVOR 
(testing acetazolamide – NCT03505788), TRANSFORM-HF (testing torsemide vs 
Furosemide – NCT03296813), EMPA-RESPONSE-AHF (testing empagliflozin in AHF – 
NCT03200860), and a trial of metolazone vs chlorothiazide (NCT03574857). The 
development of user-friendly systems to deliver subcutaneous furosemide will require 
evaluation in clinical trials.4647 
 
6.  Pharmacotherapy in heart failure with mid-range ejection fraction 











No prospective trial has been conducted in patients with HFmrEF to date. All analyses and 
related recommendations are based on post hoc analyses from HFrEF and/or HFpEF trials, 
with inclusion criteria that included patients now classified as HFmrEF. 
 
6.1. Beta-blockers for HFmrEF 
Consensus recommendation. A beta-blocker may be considered for ambulatory patients 
with symptomatic HFmrEF in sinus rhythm in order to reduce the risk of all-cause and 
cardiovascular death. 
Supporting evidence. Under the auspices of the Beta-blockers in Heart Failure 
Collaborative Group (BBmeta-HF), individual patient data (IPD) from 11 major HF clinical 
trials, comparing beta-blockers and placebo, were pooled and meta-analysed48. In a 
subgroup of 575 patients with LVEF between 40-49% in sinus rhythm (ischaemic aetiology – 
91%, NYHA class III-IV – 24%, ACE-I/ARB - 91%, MRA - 6%, diuretics - 65%), beta-blockers 
reduced the risk of all-cause and cardiovascular death (primary outcomes for this analysis). 
The absolute reduction in cardiovascular mortality in this subgroup was 4.7% (NNT to 
prevent one CV death = 21 during a median follow-up of 1.3 years)48. Beta-blockers did not 
modify the risk of either the first CV hospitalization or the composite of CV death and CV 
hospitalization (time to first event) in patients with HFmrEF in sinus rhythm. Beta-blockers 
had no effect on either primary or secondary clinical outcomes in patients with HFmrEF and 
atrial fibrillation48. 
Directions for future development. These findings should be interpreted with caution, as 
this was a post-hoc analysis. Specific trials in HFmrEF (possibly studied together with HFpEF 
patients) would be of interest. 
 
6.2. Candesartan for HFmrEF 











Consensus recommendation. Candesartan may be considered for ambulatory patients 
with symptomatic HFmrEF in order to reduce the risk of HF hospitalisation and CV death. 
Supporting evidence. The post-hoc analysis of the pooled data from the CHARM 
Programme compared the impact of candesartan on clinical outcomes in patients with HF 
across the whole spectrum of LVEF49. In a subgroup of 1,322 patients with an LVEF between 
40-49% (ischaemic aetiology – 67%, NYHA class III-IV – 42%, ACE-I - 27%, beta-blocker – 
58%, MRA - 11%, diuretics - 74%), candesartan reduced the risk of cardiovascular death and 
HF hospitalization (primary outcome for this analysis), the risk of first HF hospitalization and 
the risk of recurrent HF hospitalizations49. Candesartan did not modify the risk of either all-
cause or cardiovascular death. 
Directions for future development. These findings should be interpreted with caution, as 
this was a post-hoc analysis. However, there was no statistical interaction between LVEF 
phenotype and candesartan treatment49. Specific trials in HFmrEF (possibly studied together 
with HFpEF patients) would be of interest. 
 
6.3. Spironolactone for HFmrEF 
Consensus recommendation. Spironolactone may be considered for ambulatory patients 
with symptomatic HFmrEF without contra-indications in order to reduce the risk of 
cardiovascular death and HF hospitalisation. 
Supporting evidence. A post hoc analysis of the TOPCAT trial (spironolactone in HF with 
LVEF≥45%) suggested that in a subgroup of patients with LVEF between 44–49% (n=520), 
spironolactone reduced the risk of primary endpoint (defined as cardiovascular death, HF 
hospitalization, or resuscitated sudden death), which was mostly due to a reduction in 
cardiovascular mortality with spironolactone and most clearly observed in patients enrolled in 
North and South America50.  











Directions for future development. The evidence is based on a post-hoc analysis, in a 
small subgroup of patients classified as HFmrEF based on measurements of LVEF made by 
investigators, which will suffer from substantial measurement variability and error, in a clinical 
trial which overall was neutral. These results do, however, provide the rationale and basis for 
the design of future trials in patients with HFmrEF50, including SPIRIT-HF (EudraCT 2017-
000697-11) and SPIRRIT (NCT02901184). Given its well-proven anti-hypertensive effect, 
spironolactone may be especially useful in patients with poorly controlled hypertension.  
 
6.4.  Intravenous iron for HFmrEF 
Consensus recommendation. Evidence is insufficient to provide new practical 
recommendations. 
Supporting evidence. ID is common in patients with and without anaemia with HFrEF, 
HFmrEF and HFpEF, and is associated with worse symptoms, quality of life and clinical 
outcomes of patients with HF across the whole spectrum of LVEF51,52. Epidemiological 
evidence emphasises the need for screening for ID in patients with HF, regardless of LVEF, 
if the blood haemoglobin is <14g/dL. 
Clinical trials investigating the effects of intravenous ferric carboxymaltose in ambulatory, 
patients with symptomatic HF, LVEF ≤45% and ID (FAIR-HF, CONFIRM-HF and EFFECT-
HF) included approximately 150 patients with LVEF between 40-45% (HFmrEF).53,54,55 
Subgroup analysis by LVEF categories has not been published. 
Practical comments. All symptomatic patients with HF should have tests done for ID, if 
haemoglobin is <14g/dL.  
Directions for future development. Given the high prevalence of ID and its association with 
an unfavourable outcome in patients with HF regardless of LVEF, more clinical trial evidence 
for IV iron supplementation is awaited for HFrEF (IRONMAN – NCT02642562, AFFIRM-AHF 











– NCT02937454, FAIR-HF2 – NCT03036462, HEART-FID – NCT03037931) and HFpEF 
(FAIR-HFpEF – NCT03074591). Uncertainties also exist about the safety and efficacy of 
long-term IV supplementation, although a recent trial in patients with CKD (PIVOTAL, 
EudraCT: 2013-002267-25) does not suggest any serious issues56. The key trials, so far, 
have been conducted with ferric carboxymaltose. Whether other iron preparations are 
similarly effective and safe should be established. Controversy also exists about which test is 
best for the diagnosis of ID, and whether more than one biomarker measure is required. In 




7.  Tafamidis in cardiac transthyretin amyloidosis 
Consensus recommendation.  
- Older patients with symptomatic HF, particularly those with HFpEF (who are not 
hypertensive) or those who have features of hypertrophic or restrictive cardiomyopathy or, 
degenerative aortic stenosis and end-diastolic interventricular septal wall thickness 
exceeding 12 mm, should be considered for screening for cardiac transthyretin 
amyloidosis (ATTR).  
- Tafamidis should be considered in patients with symptomatic HF due to confirmed 
transthyretin amyloidosis (both ATTRm and ATTRwt) in order to improve exercise capacity 
and quality of life, and to reduce CV hospitalisations and mortality. This recommendation is 
limited to patients who fulfil the inclusion and exclusion criteria of the ATTR-ACT trial58 (Table 
2). These include confirmation of the presence of amyloid deposits on analysis of biopsy 
specimens obtained from the heart or other tissues (e.g., fat aspirate, gastrointestinal 
mucosa sites, salivary glands, or bone marrow). 











Special note: the cost of tafamadis is currently extremely high, therefore many patients and 
health services may currently not be able to pay for it.  
Supporting evidence. Amyloidosis includes a variety of pathologies caused by the 
extracellular accumulation of amyloid fibrils, leading to a progressive damage of the involved 
organ. When it affects the heart, it may cause HF which is often resistant to treatment and 
associated with a high mortality5960. Systemic immunoglobulin light-chain amyloidosis (AL) is 
caused by plasma cell dyscrasias that may (myeloma) or may not (monoclonal gammopathy 
of uncertain significance) be malignant. This accounts for about 80% of contemporary cases 
of cardiac amyloid and is rapidly lethal if the underlying cause cannot be reversed. 
Transthyretin amyloidosis accounts for 15-25% of all cardiac amyloidosis and has a better 
prognosis, on average, than AL amyloid. Transthyretin amyloidosis has two forms: an 
autosomal dominant inherited disease (ATTRm) and wild-type transthyretin (ATTRwt) which 
occurs sporadically. ATTR affects 20-30% of people aged >80 years and is more common in 
patients with HFpEF and/or degenerative aortic stenosis59,60,61,62,63. Novel SPECT cardiac 
imaging with bone-avid tracers (99mTc pyrophosphate (PYP), 3,3-diphosphono1,2-
propanedicarboxylic acid (DPD), and hydroxymethylene diphosphonate (HMDP)) help 
identify cases with high specificity, non-invasively64, obviating the need for endomyocardial 
biopsy.  Similarly, the myocardial radiotracer uptake during bone scintigraphy could be used 
in clinical practice, as this was >99% specific and 86% sensitive to detect cardiac ATTR 
amyloid. 65 
Tafamidis prevents transthyretin tetramer dissociation and amyloidogenesis.  In the ATTR-
ACT trial, 441 patients with transthyretin amyloid cardiomyopathy and symptoms of HF 
received, in a 2:1:2 ratio, 80 mg of tafamidis, 20 mg of tafamidis, or placebo for 30 months. 
Transthyretin amyloid cardiomyopathy (ATTRwt or ATTRm) was confirmed by the presence 
of amyloid deposits on tissue biopsies and, in patients without ATTRm, by the presence of 
transthyretin precursor protein confirmed on immunohistochemical analysis, scintigraphy, or 
mass spectrometry58. Tafamidis reduced the risk of the combined primary end-point (all-











cause death and cardiovascular-related hospitalization), independently reducing all-cause 
mortality and the rate of cardiovascular-related hospitalizations. Tafamidis also slowed the 
rate of decline in both the 6-minute walk distance and quality of life.59 
Practical comments. The high prevalence of undiagnosed transthyretin amyloidosis in older 
patients with HF, particularly those with HFpEF with or without aortic stenosis, should be 
recognised. Non-invasive, nuclear imaging simplifies diagnosis, and may in the future serve 
as preferred screening and diagnostic tool. The major obstacle for widespread 
implementation of this therapy is the very high cost of therapy.  
Directions for future development. Novel selective transthyretin stabilizers (e.g. AG10) and 
TTR gene silencers are at different stages of development66. We fully support efforts to 
reduce the high cost of this therapy.  
 
8.  Rivaroxaban in heart failure 
Consensus recommendation.   
- For ambulatory patients with CAD and CHF in NYHA class I/II with an LVEF greater than 
30%, addition of rivaroxaban 2.5mg bd to background treatment with aspirin may be 
considered in order to reduce the risk of stroke and CV death.  
- For CHF patients with a recent HF hospitalisation or persistent NYHA Class III/IV, initiation 
of treatment with rivaroxaban cannot be recommended, as there is no demonstrable 
benefit.  
Supporting evidence. The COMMANDER-HF trial enrolled 5,022 patients with chronic 
HFrEF, CAD, a recent HF hospitalisation and no AF67 and randomised them to rivaroxaban 
2.5 mg bid, added to background antiplatelet therapy; mostly aspirin but including a 
substantial proportion on dual-antiplatelet therapy. The mean follow-up was 21 months. The 











study was neutral on its primary endpoint of all-cause death, stroke or acute myocardial 
infarction. Rivaroxaban did not reduce HF hospitalization but did reduce the rate of stroke 
from 3.0% to 2.0% (HR 0.66 (0.47–0.95). A post-hoc analysis investigating the effect on a 
broad definition of vascular events (predominantly myocardial infarction, stroke and sudden 
death)68, demonstrated a significant reduction although rivaroxaban had no effect on HF 
related hospitalisations or HF deaths. There was an increase in major bleeding (from 2.0% to 
3.3%; HR 1.68 (1.18–2.39). The difference was driven mainly by the number of participants 
with a fall in haemoglobin of >2.0g/dL, with a neutral effect on bleeding requiring 
hospitalization or resulting in death. 
The COMPASS trial enrolled 27,395 patients, of whom 5,902 had HF (predominantly with 
LVEF ≥40%; n=4,250) and randomly assigned them (double-blind) to aspirin 100mg/day, 
rivaroxaban 2.5mg bd plus aspirin 100mg/day or rivaroxaban 5mg bd.69  Patients with NYHA 
class III/IV HF or a LVEF <30% were excluded. Mean follow-up was 23 months. Overall, 
compared to aspirin alone, the combination reduced stroke (from 1.6% to 0.9%; HR 0.58 
(0.44–0.76) and all-cause mortality (from 4.1% to 3.4%; HR 0.82 (0.71–0.96), but not 
myocardial infarction (from 2.2% to 1.9%) or HF hospitalisation (from 2.1% to 2.2%). Major 
bleeding events were higher on the combination (1.9% versus 3.1%; HR 1.70 [1.40–2.05]), 
although rarely fatal (10 versus 15 events). Rivaroxaban was neither superior to aspirin alone 
nor inferior to the combination. The combination exerted similar relative effects for patients 
with and without HF but the absolute gain was greater for patients with HF. For patients with 
HF, the combination reduced all-cause mortality from 6.5% to 4.4% (HR: 0.66 (0.50-0.86)). 
Benefit was clearest amongst patients with HFpEF/HFmrEF although, statistical tests could 
not confirm heterogeneity according to LV phenotype. The effect of rivaroxaban 5mg bd 
compared to aspirin 100mg/day on all-cause mortality approached significance (HR 0.80 
(0.61-1.03). Amongst patients with HF, major bleeding events were higher on the 
combination (2.5%) compared to aspirin alone (1.8%; HR 1.36 (0.88-2.09)); although the risk 











appeared somewhat less than for patients without HF (3.3 vs 1.9%, HR 1.79, 95% CI 1.45-
2.21), tests for statistical heterogeneity were not significant.  
For CHF patients with a recent HF hospitalisation or persistent NYHA Class III/IV, based on 
COMMANDER-HF, initiation of treatment with rivaroxaban cannot be recommended, 
However, stopping of pre-existing therapy with rivaroxaban in such patients cannot be 
recommended, as there is no related evidence. 
Practical comments. A large proportion of patients with advanced HF have non-valvular 
atrial fibrillation. Relevant ESC guidelines indicate that these patients should receive a 
DOAC. Rivaroxaban 2.5mg bd is not considered to be an effective dose for the prevention of 
thrombo-embolic events in patients with atrial fibrillation.  
In summary, it appears that for patients with CAD rivaroxaban 2.5mg bd in addition to low-
dose aspirin reduces the risk of vascular events in patients without HF and with mild HF. 
However, for patients with advanced HF, myocardial dysfunction and congestion rather than 
vascular events determine outcome. 
Directions for future development. These trials provide insights into the contribution of 
vascular events to the outcome of patients at various points across a broad spectrum of HF. 
The benefit and safety of aspirin in patients with HF remains in doubt, which should be 
addressed by further clinical trials. The strong trend for a reduction in mortality with 
rivaroxaban alone compared to aspirin alone (and its non-inferiority to combination therapy) 
should be investigated further. 
 
9.  Fixed dose drug combinations in heart failure 
Consensus recommendation. Evidence is insufficient to provide new practical 
recommendations. 











Supporting evidence. The incremental use of combinations of disease-modifying therapies 
has resulted in the progressive improvement in clinical outcomes for patients with HFrEF8,70  
In a network analysis, the most effective combinations for HFrEF were i) sacubitril/valsartan 
+ beta-blocker + MRA, and ii) ACE-I + beta-blocker + MRA  +  ivabradine, leading to 
reductions in all-cause mortality (versus placebo) of 62% and 59%, respectively, and in all-
cause hospitalizations of 42% for each combination.71 The administration of fixed-dose 
combinations improves compliance, blood pressure control and clinical outcomes in patients 
with hypertension but this has not yet been demonstrated for HF. 71 
Directions for future development. Many guideline-recommended medications remain 
underutilized in community practice and many fail to reach target doses. Simplifying 
medication regimens and reducing total pill intake may be welcomed by patients and health 
professionals and improve adherence. Prospective trials investigating the effects of fixed-
dose combinations should be encouraged. 
 
10.  Approaches to improving guideline adherence for drug therapy in HF 
Consensus recommendation.  Evidence is insufficient to provide new practical 
recommendations.  
Supporting evidence.  The 2016 ESC guidelines8 state that implementation of 
multidisciplinary strategies in order to improve adherence to guideline-recommended 
medicines is recommended for patients with HFrEF in order to reduce the risk of HF 
hospitalisation and cardiovascular and all-cause mortality. The ESC guidelines provide a 
framework to deliver evidence-based multidisciplinary care that translates into the better 
quality of life and improved clinical outcomes in patients with HFrEF. However, adherence to 
guideline-recommendation remains suboptimal for many reasons, including provider and 
patient education, lack of sufficient resources to advise patients, some patients’ reluctance to 
take more medication, side-effects and cost. A substantial group of patients with HF do not 











receive appropriate pharmacotherapy with adequate doses, and receives intracardiac 
devices without prior optimization of pharmacotherapy. 
In QUALIFY, an international, prospective, observational, longitudinal survey, amongst 6,669 
outpatients with HFrEF after recent HF hospitalization, good adherence for treatment with 
ACE-I, ARB, beta-blocker, MRA and ivabradine, with a prescription of at least 50% of 
recommended doses (which, however, is still less than what is achieved in many trials), was 
associated with a better clinical outcomes during 6-month follow-up (e.g. reduced mortality)72. 
Similarly, in the BIOSTAT-CHF study, which was specifically designed to study up-titration of 
ACE-I/ARB and/or beta-blocker and enrolled 2,516 patients with worsening HF, those treated 
with less than 50% of recommended doses had a greater risk of death and/or HF 
hospitalization73. 
Directions for future development. There is a need to develop more practical strategies to 
improve adherence to guidelines. They should be based on multidisciplinary models, 
involving HF teams, structured referral schemes, telemedicine (using home-based 
methodology or also implantable pulmonary artery pressure and left atrial pressure 
monitoring systems, synchronized education of patients and health care providers, care 
standardization, quality control and audit. The development of centres of excellence, such as 
those recently described for the treatment of advanced HF74 may contribute to this goal. 
 
B –  DEVICE BASED THERAPIES 
 
11.  Implantable cardioverter-defibrillators  
Consensus recommendation.   
- The consensus group did not identify any new evidence to alter the 2016 guideline 
recommendations8 on ICD implantation in patients with HFrEF and CAD.  











- The consensus view was that one may consider not to implant an ICD in patients with 
non-ischaemic HFrEF who i) are aged >70 years, or ii) have advanced symptoms (NYHA 
III/IV), or iii) have life-shortening co-morbidity (e.g. severe lung disease or Stage IV CKD) 
and hence are likely to die for reasons other than sudden arrhythmic death.  
Supporting evidence. A randomised trial of patients with non-ischaemic symptomatic HF 
and an LVEF ≤35% (DANISH) did not show that implanting an ICD for primary prevention 
reduced overall mortality despite a reduction in sudden deaths75. Many patients had a broad 
QRS and were randomised to receive CRT-P or CRT-D (58% of participants) but, similar to 
the main trial, no difference in mortality was observed in this subgroup. For patients aged 
<59 years, implantation of an ICD almost halved mortality but for those aged 59-67 years 
mortality was reduced by only 25% and for those aged 68 years or older, there was a 19% 
excess mortality. ICDs probably reduce SCD throughout the age-spectrum but fail to reduce 
all-cause mortality in older patients due to high rates of death due to worsening HF and non-
cardiac co-morbidities. Patients with an NT-proBNP above about 1,000pg/mL did not benefit 
from an ICD. Pharmacological therapy should be optimized before a decision is made to 
implant an ICD. The risk of deferring ICD implantation by a few months in order to optimise 
therapy is low.  
The benefit of the ICD is determined by the risk of sudden cardiac death over the risk of non-
sudden cardiac death incorporating the high co-morbidity burden in HF patients. The rate of 
SAD appears to be declining, possibly due to improvements in pharmacological care76, which 
might reduce the absolute effect of ICDs on mortality. For patients with a LVEF ≤35% who do 
not have CAD, the most recent trial reported an annual risk of SAD of about 1% in patients 
who were assigned not to receive an ICD.  
 











Practical comments.  For younger patients (e.g. <70 years), implantation of an ICD is 
recommended provided the patient is considered unlikely to die of a cause other than SAD in 
the following 5 years (predicted reduction in mortality over 5 years of up to 5%). 
Directions for future development. More trials comparing CRT-P and CRT-D are required, 
such as RESET-CRT (NCT03494933). The VEST trial (Vest Prevention of Early Sudden 
Death)77 showed a reduction in mortality although not SAD in patients with an acute 
myocardial infarction and an LVEF <35%. Trials for patients with HF may be warranted 
although, given the generally low annual risk of SAD, this intervention may only be useful for 
some highly selected patient groups.  
 
12.  Atrial fibrillation ablation 
Consensus recommendation.   
- Pulmonary vein ablation of patients with HF and symptomatic paroxysmal atrial fibrillation 
may be considered, if paroxysms cause troublesome symptoms despite implementation of 
guideline-recommended pharmacological and device therapy.  
- Atrio-ventricular node ablation, usually with bi-ventricular rather than right ventricular 
pacing, may be considered if paroxysms provoke severe symptoms and pulmonary vein 
ablation has failed or is not possible. 
- Pulmonary vein ablation for persistent atrial fibrillation may be considered for patients with 
HFrEF who have an implanted device (to prevent bradycardia; ICD, CRT or PPM) if 
achieving and maintaining sinus rhythm is considered likely, especially if the onset of AF was 
associated with a deterioration in symptoms of HF or the patient has (or is a candidate for) 
CRT. Pulmonary vein ablation is less likely to be successful in patients with long-standing AF 
and severe right and or left atrial dilatation. 











- Atrio-ventricular node ablation is not recommended in patients with CRT and AF with 
controlled heart rate due to a lack of evidence of clinical benefit that ablation is superior to 
pharmacological rate control. 
Supporting Evidence.  The debate on whether rate or rhythm control is the better strategy 
for managing atrial fibrillation (AF) complicating HF continues. Anti-coagulants should be 
continued even if sinus rhythm is restored because the risk of recurrent AF is high. An 
optimal rate-control strategy must avoid excessive heart rate reduction as well as toxic anti-
arrhythmic agents, potentially including higher doses of amiodarone or plasma 
concentrations of digoxin. A modest dose of beta-blocker may be the safest option for rate-
control in patients with AF, even if beta-blockers do not appear to improve outcome when 
titrated to conventional target doses78. A rate control strategy for persistent AF avoids the 
need for procedures and potentially toxic drugs and the problems that relapse into AF can 
cause. For those with symptomatic paroxysmal AF and HF there is a stronger rationale for a 
rhythm control strategy.  
There is no substantial trial investigating PV or AV node ablation for paroxysmal AF in 
patients with HF. However, where there is a clear association between paroxysmal AF and 
marked worsening of symptoms which persist despite guideline-recommended therapy, then 
PV ablation or, if that fails, AVN ablation should be considered,  
Patients (n=3,103) with HF and persistent AF were evaluated for inclusion in the CASTLE-AF 
trial comparing pharmacological rate or rhythm control with pulmonary vein ablation in 
patients with HFrEF (LVEF <35%) and an ICD or CRT-D device (to prevent post-ablation 
bradycardia)79. Finally, only 363 patients were randomised (about 50 patients per year) of 
whom only 317 received their assigned strategy. PV ablation often failed, with a residual 
burden of AF of about 25%. Neither patients nor investigators were blind to assigned 
management strategy and 33 patients were lost to follow-up. A reduction in the primary 
composite endpoint of death from any cause or hospitalization for worsening HF was 











reported for the intervention arm patients (28% vs 45%, hazard ratio 0.62, 95% confidence 
interval 0.43 – 0.87). The effect was consistent over primary endpoint composites (Hazard 
ratio of 0.53 and 0.56, respectively, p0.01 for both). After 3-years of follow-up, at which time 
there were fewer than 100 patients in each group, a difference in mortality appeared (24 
deaths with ablation versus 46 deaths in control). Patients with less advanced HF (EF>25%, 
NYHA class II, <65 years old) potentially derived greater benefit. 
The CABANA trial also compared PV ablation to medical therapy8081. Only 337 of 2,204 
patients randomised had HF at baseline. Overall, the trial was neutral for its primary 
composite endpoint [HR 0.86, 95% confidence interval 0.65-1.15]. The point-estimate was 
somewhat better for patients with HF [HR 0.61, 95%CI 0.35-1.08], and was associated with 
an improvement in quality of life at 12 months.  
A meta-analysis of older trials reported 18 deaths amongst patients assigned to control 
compared to 9 assigned to ablation82. In summary, the data suggesting that a rhythm rather 
than rate control strategy is superior is not robust for patients with persistent AF. The trials 
were not blinded and the patients highly selected. Further trials are required. 
Several trials show that bi-ventricular pacing is superior to RV pacing after AV node 
ablation83. This may reflect the deleterious effects of RV pacing rather than any benefit of bi-
ventricular pacing. The landmark trials all required patients to be in sinus rhythm. CRT may 
require atrio-ventricular as well as bi-ventricular resynchronisation to be effective. A small, 
(n=102) un-blinded trial comparing AV node ablation with pharmacological treatment 
suggested benefit to the ablation strategy but there were too few events to be convincing84. 
Accordingly, the consensus opinion was to avoid this strategy until more evidence of benefit 
is obtained.  
Although AV node ablation will increase bi-ventricular capture, there is no evidence from 
adequately-designed RCTs that this improves patient well-being or outcome.785 











Practical comments.  Ensure that the patient is receiving an effective anticoagulant 
regimen. The optimal resting ventricular rate for patients with HF and AF may be 70-90bpm. 
Anti-arrhythmic agents should generally be avoided other than to control symptomatic 
paroxysmal AF; PV ablation may be a better strategy than amiodarone/dronedarone, the 
latter is contraindicated in HF. Ablation is best reserved for patients with paroxysmal AF 
where episodes cause marked worsening of symptoms despite guideline-recommended 
therapy at optimal doses. There is little evidence of benefit from CRT in the absence of sinus 
rhythm or that AVN ablation to increase biventricular capture improves outcomes. AVN 
ablation should be an intervention of last resort. PV ablation to restore sinus rhythm is 
preferred in patients with CRT. Neither the safety nor efficacy of PV ablation for persistent AF 
and HF in the absence of back-up pacing has been demonstrated.  
Directions for future development.  
The group believes that a series of RCTs is required comparing “non-aggressive” 
pharmacological rate control, avoiding amiodarone or Class I anti-arrhythmic agents and 
higher doses or plasma concentrations of digoxin with the following procedures: 
1.) PV (and/or AVN) ablation for paroxysmal AF and HF vs “non-aggressive” 
pharmacological rate control (and avoiding all of: amiodarone, Class I anti-arrhythmic agents, 
higher doses or higher plasma concentrations of digoxin) 
2.) PV (and/or AVN) ablation for persistent AF and HF with or without a back-up 
pacing device vs “non-aggressive” pharmacological rate control (and avoiding all of: 
amiodarone, Class I anti-arrhythmic agents, higher doses or higher plasma concentrations of 
digoxin) 
3.) PV (and/or AVN) ablation in HF patients with CRT vs usual care 
There is also a need for RCTs comparing different rate control strategies, including  
4.) High- versus low-dose beta-blocker  











5.) Addition of digoxin to beta-blockers. The ongoing DIGIT-HF trial includes patients 
with AF, but excludes patients in need of rate control with digitalis glycosides. 86 
There is also a need for RCTs investigating  
6.) new agents for pharmacological rhythm-control (double-blind versus placebo),  
7.) prevention of AF (double-blind versus placebo) 
8.) better treatments to prevent atrial fibrillation recurrence (double-blind versus 
placebo 
 
13. MitraClip  
Consensus recommendation.  
- Referral of patients with HF and secondary (i.e. functional) mitral regurgitation to a 
multidisciplinary HF team that will decide on management is recommended.  
- Reduction in mitral regurgitation using a MitraClip device may be considered for patients 
with HFrEF who fulfil the COAPT87 selection criteria (Table 3).  
Supporting evidence. The MITRA-FR88 and COAPT87 trials (recruiting 303 and 614 
patients, respectively) included different populations and reported very different results on 
the clinical efficacy of MitraClip.  In COAPT, patients assigned to MitraClip were more likely 
to be prescribed ACE-I, ARB or ARNI at baseline (72% compared to 63%, p = 0.02). By 12 
months this difference had increased (77% compared to 63%, p = 0.002) and more patients 
assigned to MitraClip were receiving beta-blockers (93% versus 87%, p=0.02).  In COAPT, 
the baseline LVEF was 31% (MITRA-FR 33%), the left-ventricular end-diastolic diameter was 
was 62±7 mm (in MITRA-FR 68±8 mm), and the effective regurgitant orifice area was on 
average 40±15 mm2 (vs 31±10 mm2 in MITRA-FR).  Over 24 months, COAPT reduced HF 











hospitalisations by 47% (p<0.001), and all-cause mortality (by 38%, p<0.001) and improved 
improved average 6min-walking test distance by >50 m (p<0.001). Over a follow-up of 12 
months, no such benefits were observed in MITRA-FR. However, the outcome of these two 
trials at one year were not statistically different7. Longer-term follow-up for the MITRA-FR trial 
might reveal a deferred benefit. 
 
Practical comments.  If interventional therapy is considered, a multidisciplinary team 
involving HF specialists, interventionalists, imaging experts and cardiac surgeons should be 
involved in patient evaluation and decision making. Medical therapy should be optimised 
before deciding on intervention. Treatment with sacubitril/valsartan for HFrEF may also be of 
some importance as demonstrated recently in the PRIME trial89.  Of note, the PRIME study 
was a small (n=118) double-blind RCT comparing sacubitril/valsartan to Valsartan alone in 
HF patients with chronic functional MR.  The primary end-point, the reduction in echo-derived 
effective regurgitant orifice area, was reached at a borderline level of significance (–
0.058±0.095 versus –0.018±0.105 cm2; P=0.032). The trial was too small to show any clinical 
benefits and echo derived parameters of MR severity are not considered to constitute 
evidence of clinical benefit.  The ratio of the severity of MR to the severity of LV dilatation 
may be a key determinant of the response to mitral valve repair; patients with 
disproportionately severe MR may benefit more. 
 
Directions for future development.  The Reshape-HF2 trial (NCT02444338) is on-going 
and will have more patient-years follow-up than either published trial.  
 
14.  Treatment of central sleep apnoea 
Consensus recommendation.  











- Patients with HF and suspected sleep apnoea who are being considered for positive 
pressure airway mask therapy are recommended to undergo a specialized sleep study in 
order to diagnose the characteristics of the sleep apnoea present, in particular whether the 
sleep apnoea is predominantly obstructive or central in nature. 
- In patients with predominantly central sleep apnoea (CSA) and concomitant HFrEF, 
evidence is insufficient to recommend CSA therapy for any putative benefit in the HF itself, 
and treatments directed at the CSA should be reviewed and avoided, unless compelling 
symptomatic indications for treatment of the CSA exist, in which case positive pressure 
airway mask therapy should be avoided and phrenic nerve stimulation may be considered 
as an alternative.  
Supporting evidence. HFrEF patients with predominantly CSA suffered an increase in 
mortality in SERVE-HF90, so that it is essential to know if such patients have CSA prior to 
starting positive airway pressure therapy. One small trial (Pivotal trial91) showed promise for 
phrenic nerve stimulation (PNS) for the treatment of severe central sleep apnoea. However, 
the randomised trial included only 151 patients (73 assigned to PNS) of whom only 96 had 
HF (48 assigned to PNS – and perhaps only half of these had HFrEF) and follow-up was for 
only 6 months. PNS improved AHI and symptoms, although blinding may have been 
imperfect; two deaths occurred in each group. 
Practical comments. PNS received FDA approval in 2018 and is also reimbursed in a 
number of European Countries. Further clinical trials are required before making positive 
recommendations. The learning curve for this new therapeutic approach is considered to be 
3-10 cases for experienced interventionalists. Patients can on occasion feel the stimulation, 
an effect which reduces over a few weeks. The device is designed to stimulate only during 
sleep, thereby reducing the chance of on-going stimulation awareness. 
 











Directions for future development. The prevalence of CSA to some degree depends on 
the disease definition and HF severity. A study to investigate the impact on morbidity and 
mortality of phrenic nerve stimulation is required before making recommendations for 
broader use in the HF population.  
 
15.  Cardiac contractility modulation 
Consensus recommendation.  CCM may be considered in patients with HFrEF (LVEF 
between 25-45%) and a narrow QRS complex (<130 ms) in order to improve exercise 
capacity, quality of life and alleviate HF symptoms. 
Supporting evidence. In the FiX-HF 5C trial92, CCM increased peak VO2 by 0.84 (95% 
Bayesian credible interval: 0.123 to 1.552) ml O2/kg/min (the primary end-point), and the 
Minnesota Living With Heart Failure questionnaire (p < 0.001), NYHA functional class (p < 
0.001), and 6-min hall walk (p = 0.02). This trial used an FDA-approved design and analysis 
to confirm the results on an earlier sub-group analysis.  Although its limitations, i.e. the 
unblinded nature, and a small sample size (160 patients), with short follow-up duration (24 
weeks), not powered to look at outcomes, the point estimate showed the composite of 
cardiovascular death and HF hospitalizations reduced from 10.8% to 2.9% (p = 0.048). 
Practical comments. CCM is now approved in the US and Europe. CCM may be used to 
improve symptoms and exercise capacity in selected HFrEF patients with troublesome 
symptoms despite pharmacological therapy who have a QRS duration of <130msec and are 
therefore not indicated for CRT.  
Directions for future development.  A study to investigate the impact on morbidity and 
mortality is being planned. 
 
16. Mechanical ventricular assist devices 











Consensus recommendation.  There is limited evidence to make new recommendations. 
For patients with advanced HF that are considered for implantation of a HeartMate – LVAD 
device, a HeartMate III rather than HeartMate II device should be considered.  
Supporting evidence. ROADMAP93 tested the HeartMate II vs optimized medical therapy as 
destination therapy. No difference for survival was found, but use of HeartMate II was 
associated with better functional capacity and quality of life. ENDURANCE94 tested the 
HeartMate HVAD System vs HeartMate II in patients with advanced HF eligible for heart 
transplantation, and showed non-inferiority for the HVAD System, however, stroke and 
device malfunction rates were increased with this system. MOMENTUM 395 is a pivotal trial 
for HeartMate III vs HeartMate II. Use of HeartMate III was associated with better 2-year 
survival and fewer adverse events.  
 
C – DISEASE MANAGEMENT AND LIFE STYLE 
 
16.  Multidisciplinary heart failure management programs 
Consensus recommendation. As already stated in the 2016 ESC HF Guidelines, it is 
recommended that HF patients are enrolled in a multidisciplinary HF management program. 
Both home-based and clinic-based programs can improve outcomes. Self-management 
strategies are encouraged.  
Supportive evidence. Although evidence on the effectiveness of multidisciplinary HF 
management program was established in the 2016 guidelines8, new studies have been 
published since then, often investigating the optimal components and intensity of these 
programs. In 2017, van Spall et al.96 published a network meta-analysis of 53 RCTs, 
concluding that both nurse home-visits and disease management clinics reduced all-cause 
mortality compared to usual care; nurse home-visits being most effective. Jonkman et al.97 











published an IPD meta-analysis of 20 studies, including 5,624 patients, and concluded that 
self-management interventions in HF patients improve outcomes despite heterogeneity 
diversity in intensity, content and personnel who deliver the intervention. 
Directions for future development. Studies addressing the benefits of multi-disciplinary HF 
disease management programmes, barriers and opportunities for their implementation and 
interactions and synergies with a variety of health care systems would be valuable.  
 
17.  Salt/sodium intake 
Consensus recommendation. There is no robust new evidence on the benefits of 
manipulating salt intake on clinical status amongst either out-patients or in-patients.  
Supportive evidence. A recent systematic review,98 identified nine trials involving 479 
unique participants, none including more than 100 patients; results were inconclusive. 
Although there was a trend toward improvement in the clinical signs and symptoms of heart 
failure with reduced intake of dietary salt, no clinically relevant data on whether reduced 
dietary salt intake affected outcomes such as cardiovascular-associated or all cause 
mortality, cardiovascular-associated events, hospitalization, or length of hospital stay were 
found. 
Direction for future development.  Several trials  investigating salt restriction in HF are in 
progress.  Sodium, chloride and water balance are all important.  Oedema and congestion 
are volumetrically mainly due to water. Many patients with severe HF have hyponatraemia. 
Ensuring that net loss of water exceeds that of salt may be important for the management of 
oedema. Well-designed, adequately powered studies are needed to reduce uncertainty 
about the sodium restriction in HF patients 
 
18.  Exercise based cardiac rehabilitation 











Consensus recommendation. It is recommended that patients with HF with reduced EF 
are enrolled in an exercise-based cardiac rehabilitation programme to reduce the risk of HF 
hospitalization.  
Supportive evidence.  A new meta-analysis99 and an updated Cochrane meta-analysis100 
identified 44 trials that included 5,783 people with HFrEF both showed that exercise 
rehabilitation reduced hospital admissions overall, as well as for HF. The effect on health-
related quality of life is uncertain due to lower-quality evidence. However, neither the 
participants nor investigators were blind to intervention and many older patients with HF will 
have been excluded due to their inability to comply with trial requirements.  
Directions for future development. Further evidence is needed to show whether exercise 
rehabilitation benefits older, frailer patients and those with HFpEF (currently under 
investigation) as well as the impact of and alternative delivery settings including home- and 
using technology-based programmes101.  
 
19. Telemedicine  
Consensus recommendation.  Home telemonitoring using an approach that is similar to the 
one used in TIM-HF2 may be considered for patients with HF in order to reduce the risk 
recurrent cardiovascular and HF hospitalizations and cardiovascular death.   
Supporting evidence. The TIM-HF2 trial102 included 1,571 patients and demonstrated that 
remote telemonitoring including home assessment of weight, blood pressure, ECG and 
general health status in the context of a 24/7 support system, reduced the proportion of days 
lost due to unplanned CV (mainly HF) hospitalizations or death (p=0.046). This study also 
documented a reduction in all-cause mortality for patients managed using telemedicine (HR 
0.70, p=0.028). 
Of note, through an oversight, the 2016 ESC Guidelines8 failed to refer to a systematic 
Cochrane review of home telemonitoring published in late 2015 (after the guideline had done 











its major literature search). This Cochrane review103 identified 25 relevant trials and found 
that telemonitoring reduced all-cause mortality by about 20% and HF hospitalisation by about 
30%. 
Practical comments. Home telemonitoring may be used to enhance patient education and 
motivation and delivery of care but must be adapted to work in synergy with existing 
healthcare provision. Remote monitoring should not be impersonal. As with many 
interventions, the cost/benefit needs to be adequately assessed.  
Directions for future development. Further research is required and will be facilitated by 
advances in sensor and communication technology, smart algorithms and machine-learning 
and the growing number of effective interventions that require monitoring. The TIM-HF2 
intervention protocol should be tested in other countries and different health-care systems.   
 
Section D. Summary and outlook 
It is approximately three years since the cut-off date for clinical trial data to be considered in 
the most recent HFA guidelines on HF8 and it will be more than another two years before we 
have the next ESC guidelines on HF (in 2021). As such this expert consensus meeting report 
of The Heart Failure Association of the European Society of Cardiology gives us a chance to 
review significant developments in pharmacotherapy, interventions, device therapy and 
general care relevant to the management of HF. As stated before, this expert consensus 
report does not aim to be a guideline update nor a position statement. 
 
Specific new recommendations have been made based on the evidence from major trials 
published since 2016, including SGLT2 inhibitors in T2DM; MitraClip for functional MR; atrial 
fibrillation ablation in HF; Tafamidis in cardiac transthyretin amyloidosis; Rivaroxaban in HF; 
ICD’s in non-ischaemic HF; and telemedicine for HF. In addition, new trial evidence from 











smaller trials and updated meta-analyses have given us the chance to refine our guidance 
statements in selected other areas.  
 
Further, new trial evidence is due in many of these areas and others over the next two years, 
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ACE-I – angiotensin-converting enzyme inhibitors  
ADVOR – Acetazolamide in Decompensated Heart Failure With Volume OveRload 
AHF – acute heart failure 
AHI – Apnea–Hypopnea Index 
AF – atrial fibrillation 
AFFIRM-AHF – Study to Compare Ferric Carboxymaltose With Placebo in Patients With 
Acute Heart Failure and Iron Deficiency 
AL – amyloidosis  
AMETHYST-DN – Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension 
and Diabetic Nephropathy 
ARBs – angiotensin receptor blockers  
ARNI – angiotensin receptor-neprilysin inhibitor 
ATTR – cardiac transthyretin amyloidosis  
ATTR-ACT – Safety and Efficacy of Tafamidis in Patients With Transthyretin 
Cardiomyopathy  
ATTRm – hereditary cardiac transthyretin amyloidosis 
ATTRwt – wild-type cardiac transthyretin amyloidosis 
AVN ablation– atrioventricular node ablation 
BIOSTAT-CHF study – BIOlogy Study to TAilored Treatment in Chronic Heart Failure 
BNP – b-type natriuretic peptide 
CABANA trial – Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial 
CAD – coronary artery disease  
CANTOS trial – Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV 
Disease Events) 
CANVAS – CANagliflozin cardioVascular Assessment Study 











CASTLE-AF trial – Catheter Ablation vs. Standard Conventional Treatment in Patients With 
LV Dysfunction and AF 
CCM – Cardiac contractility modulation 
CHARM – Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity 
CHF – chronic heart failure 
CKD – chronic kidney disease 
COAPT trial – Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy 
for Heart Failure Patients With Functional Mitral Regurgitation 
COMMANDER HF trial – A Study to Assess the Effectiveness and Safety of Rivaroxaban in 
Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure 
and Coronary Artery Disease Following an Episode of Decompensated Heart Failure  
COMPASS trial – Rivaroxaban for the Prevention of Major Cardiovascular Events in 
Coronary or Peripheral Artery Disease  
CONFIRM-HF – A Study to Compare the Use of Ferric Carboxymaltose With Placebo in 
Patients With Chronic Heart Failure and Iron Deficiency 
CREDENCE trial – Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular 
Outcomes in Participants With Diabetic Nephropathy 
CRT – cardiac resynchronization therapy 
CRT-D – cardiac resynchronization therapy defibrillator 
CRT-P – cardiac resynchronization therapy pacemaker  
CSA – central sleep apnoea  
CV – cardiovascular  
DANISH – Danish ICD Study in Patients With Dilated Cardiomyopathy 
DECLARE-TIMI 58 trial – Multicenter Trial to Evaluate the Effect of Dapagliflozin on the 
Incidence of Cardiovascular Events 
DIAMOND – Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi 
Medications for the Treatment of Heart Failure  
EFFECT-HF – Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron 
Deficiency and Chronic Heart Failure 











eGFR – estimated glomerular filtration rate 
EMPA-REG OUTCOME trial – BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial 
in Type 2 Diabetes Mellitus Patients 
EMPA-RESPONSE-AHF – Effects of Empagliflozin on Clinical Outcomes in Patients With 
Acute Decompensated Heart Failure 
ENDURANCE trial – The HeartWare™ Ventricular Assist System as Destination Therapy of 
Advanced Heart Failure 
ESC – European Society of Cardiology 
FAIR-HF – A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients 
With Chronic Heart Failure and Iron Deficiency 
FAIR-HF2 – Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to 
Improve Morbidity & Mortality 
FAIR-HFpEF – Effect of IV Iron in Patients With Heart Failure With Preserved Ejection 
Fraction 
FDA – Food and Drug Administration 
FiX-HF 5C trial – Evaluate Safety and Efficacy of the OPTIMIZER® System in Subjects With 
Moderate-to-Severe Heart Failure 
HF – heart failure 
HFA – Heart Failure Association 
HFmrEF – heart failure with mid-range ejection fraction 
HFrEF – heart failure with reduced ejection fraction 
HFpEF – heart failure with preserved ejection fraction 
HR – hazard ratio 
ICD – implantable cardioverter defibrillator  
ID – iron deficiency  
IPD – individual patient data  
IRONMAN – Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency 
kg – kilogram  











LVAD – left ventricular assist device 
LVEF – left ventricular ejection fraction 
min – minute 
MITRA-FR trial – Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in 
Patients With Severe Secondary Mitral Regurgitation  
mL – milliliter 
MOMENTUM 3 – Multi-center Study of MagLev Technology in Patients Undergoing MCS 
Therapy With HeartMate 3™ IDE Clinical Study 
MR – mitral regurgitation  
MRA – mineralocorticoid receptor antagonist  
NNT – number needed to treat 
NT-proBNP – N-terminal pro b-type natriuretic peptide 
NYHA – New York Heart Association  
O2 – oxygen 
PARADIGM-HF trial – This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared 
to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure 
PARADISE-MI – Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in 
Reducing Heart Failure Events After MI  
PARAGON-HF trial – Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity 
and Mortality in Heart Failure Patients With Preserved Ejection Fraction 
PEARL-HF – Evaluation of Patiromer in Heart Failure Patients 
PIONEER-HF trial – Comparison of Saocubitril/valsartaN Versus Enalapril on Effect on 
ntpRo-bnp in Patients Stabilized From an Acute Heart Failure Episode.  
PIVOTAL trial – UK Multicentre Open-label Randomised Controlled Trial Of IV Iron Therapy 
In Incident Haemodialysis Patients 
Pivotal trial – A Randomized Trial Evaluating the Safety and Effectiveness of the remedē® 
System in Patients With Central Sleep Apnea 
PNS - phrenic nerve stimulation  











PPM – permanent pacemaker  
PRIME study – Pharmacological Reduction of Functional, Ischemic Mitral Regurgitation 
PRIORITIZE HF – Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With 
Sodium Zirconium Cyclosilicate in Heart Failure 
PV ablation– pulmonary vein ablation 
QUALIFY survey – QUality of Adherence to guideline recommendations for LIFe‐saving 
treatment in heart failure surveY 
RAAS-I – renin angiotensin aldosterone system inhibitors 
RESET-CRT – Re-evaluation of Otimal Re-synchronisation Therapy in Patients with CHF 
Reshape-HF2 – A Clinical Evaluation of the Safety and Effectiveness of the MitraClip System 
in the Treatment of Clinically Significant Functional Mitral Regurgitation  
ROADMAP trial – Risk Assessment and Comparative Effectiveness of Left Ventricular Assist 
Device (LVAD) and Medical Management  
SAD – sudden arrhythmic death  
SERVE-HF – Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation 
in Patients With Heart Failure 
SGLT2 – Sodium glucose transporter 2 
SPECT – single photon emission computed tomography 
SPIRIT-HF – SPIRonolactone In the Treatment of Heart Failure 
SPIRRIT-HFPEF – Spironolactone Initiation Registry Randomized Interventional Trial in 
Heart Failure With Preserved Ejection Fraction 
T2DM – type 2 diabetes  
TIM-HF2 – Telemedical Interventional Management in Heart Failure II 
TOPCAT trial – Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved 
Systolic Function 
TRANSFORM-HF – ToRsemide compArisoN With furoSemide FORManagement of Heart 
Failure  
TRANSITION trial – Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in 
HFrEF Patients After an Acute Decompensation Event 











TTR – transthyretin 
VEST trial – Vest Prevention of Early Sudden Death 
ZS-9 – sodium zirconium cyclosilicate 
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e Table 1 
Eighteen Ongoing Randomised Trials of SGLT2-inhibitors in Patients with Heart Failure 
SGLT2 inhibitor Trial name Primary outcome Disease  N 
Empagliflozin EMPEROR-Preserved1 Time to first CV death or hospitalization for HF HFpEF ca. 5500 
Dapagliflozin DAPA-HF2 
Time to first CV death, hospitalization for HF, or 




Time to first occurrence of CV death, 
hospitalization for HF, urgent HF visit  
HFpEF 
ca. 4700 
Sotagliflozin SOLOIST-WHF4 Time to first CV death or hospitalization for HF HFrEF 4000 
Empagliflozin EMPEROR-Reduced5 Time to first CV death or hospitalization for HF HFrEF ca. 3350 
Dapagliflozin PRESERVED-HF6 Change of NT-proBNP HFpEF 320 









e Empagliflozin EMPERIAL-reduced7 Change in 6-minute walk distance HFrEF 300 
Empagliflozin EMPERIAL-Preserved8 Change in 6-minute walk distance HFpEF 300 
Dapagliflozin DETERMINE-reduced9 Change in 6-minute walk distance HFrEF 300 
Dapagliflozin DETERMINE-preserved10 Change in 6-minute walk distance HFpEF 400 
Dapagliflozin DEFINE-HF11 Change of NT-proBNP HFrEF 263 
Empagliflozin Empire HF12 Change of NT-proBNP HFrEF 189 
Empagliflozin SUGAR13 Left Ventricular End Systolic Volume Index and  left ventricular global longitudinal strain 
HFrEF 130 
Ertugliflozin ERTU-GLS14 Global Longitudinal Strain  HF 120 
Empagliflozin NCT0375308715 Change in 6-minute walk distance HFpEF 100 
Empagliflozin NCT0333221216 Change in PCr/ATP ratio in the resting state HF 86 









e Empagliflozin ELSI17 Skin sodium content  HFrEF 84 
Empagliflozin EMBRACE-HF18 Change in pulmonary artery diastolic pressure HF 60 
 
  









e Table 2 
Inclusion/exclusion criteria of the ATTR-ACT trial (copied from19) 
Exclusion Criteria:  
1. they had, in the opinion of the investigator, heart failure that was not due to 
transthyretin amyloid cardiomyopathy 
2. New York Heart Association (NYHA) class IV heart failure 
3. the presence of light-chain amyloidosis 
4. a history of liver or heart transplantation 
5. an implanted cardiac device 
6. previous treatment with tafamidis 
7. an estimated glomerular filtration rate lower than 25 ml per minute per 1.73 m2 of 
body-surface area 
8. liver transaminase levels exceeding two times the upper limit of the normal range.  
9. severe malnutrition as defined by a modified body-mass index (mBMI) of less than 
600 calculated as the serum albumin level in grams per liter multiplied by the 
conventional BMI (the weight in kilograms divided by the square of the height in 










10. concurrent treatment with nonsteroidal antiinflammatory drugs, 













e Table 3 
Inclusion/exclusion criteria from the COAPT trial (copied from20) 
Inclusion criteria (all must be present) 
1.  Symptomatic secondary mitral regurgitation (3+or 4+ by independent 
echocardiographic core laboratory assessment) due to cardiomyopathy of either 
ischemic or non-ischemic etiology  
2.  Subject has been adequately treated per applicable standards, including for coronary 
artery disease, LV dysfunction, mitral regurgitation and heart failure 
3.  NYHA functional class II, III or ambulatory IV 
4.  Subject has had at least one hospitalization for heart failure in the 12 months prior to 
enrollmentand/or a corrected* BNP ≥300 pg/ml or a corrected NT-proBNP ≥1500 
pg/ml  
5.  Local heart team has determined that MV surgery will not be offered as a treatment 
option, even if the subject is randomized to the Control group 
6.  Left ventricular ejection fraction ≥20% and ≤50%. 
7.  Left ventricular end-systolic dimension ≤70 mm 









e 8.  The primary regurgitant jet is non-commissural, and in the opinion of the MitraClip 
implanting investigator can be successfully be treated by the MitraClip (if a secondary 
jet exists, it must be considered clinically insignificant) 
9.  CK-MB obtained within prior 14 days is less than thelocal laboratory ULN  
10.  Transseptal catheterization and femoral vein access is feasible per the MitraClip 
implanting investigator 
11.  Age 18 years or older 
12.  Subject or guardian agrees to all provisions of the protocol, including the possibility of 
randomization to the Control group and returning for all required post-procedure 
follow-up visits, and has provided written informed consent  
 
Exclusion criteria (all must be absent)  
1.  Untreated clinically significant coronary artery disease requiring revascularization 
2.  CABG, PCI or TAVR within the prior 30 days  
3.  Aortic or tricuspid valve disease requiring surgery or transcatheter intervention 
4.  COPD requiring continuous home oxygen therapy or chronic outpatient oral steroid 
use 









e 5.  Cerebrovascular accident within prior 30 days  
6.  Severe symptomatic carotid stenosis (>70% by ultrasound) 
7.  Carotid surgery or stenting within prior 30 days 
8.  ACC/AHA stage D heart failure 
9.  Presence of any of the following: Estimated PASP >70 mm Hg assessed by site 
based on echocardiography or right heart catheterization, unless active vasodilator 
therapy in the cath lab is able to reduce the 12PVR to <3 Wood Units or between 3 
and 4.5Wood Units with v wave less than twice the mean of the PCWP•Hypertrophic 
cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other 
structural heart disease causing heart failure other than dilated cardiomyopathy of 
either ischemic or non-ischemic etiology•Infiltrative cardiomyopathies (e.g., 
amyloidosis, hemochromatosis, sarcoidosis) 
10.  Hemodynamic instability requiring inotropic support or mechanical heart assistance 
11.  Physical evidence of right-sided congestive heart failure with echocardiographic 
evidence of moderate or severe right ventricular dysfunction 
12.  Implant of CRT or CRT-D within the last 30 days  
13.  Mitral valve orifice area <4.0 cm2by site-assessed TTE 









e 14.  Leaflet anatomy which may preclude MitraClip implantation, proper MitraClip 
positioning on the leaflets or sufficient reduction in mitral regurgitationby the MitraClip. 
15.  Hemodynamic instability defined as systolic pressure < 90 mmHg with or without 
afterload reduction, cardiogenic shock or the need for inotropic support or intra-aortic 
balloon pump or other hemodynamic support device. 
16.  Need for emergent or urgent surgery for any reason or any planned cardiac surgery 
within the next 12 months. 
17.  Life expectancy <12 months due to non-cardiac conditions 
18.  Modified Rankin Scale ≥4 disability. 
19.  Status 1 heart transplant or prior orthotopic heart transplantation 
20.  Prior mitral valve leaflet surgery or any currently implanted prosthetic mitral valve, or 
any prior transcatheter mitral valve procedure. 
21.  Echocardiographic evidence of intracardiac mass, thrombus or vegetation 
22.  Active endocarditis or active rheumatic heart disease or leaflets degenerated from 
rheumatic disease (i.e., noncompliant, perforated) 
23.  Active infections requiring current antibiotic therapy 
24.  Transesophageal echocardiography (TEE) is contraindicated or high risk 









e 25.  Known hypersensitivity or contraindication to procedural medications which cannot be 
adequately managed medically 
26.  Pregnant or planning pregnancy within next 12 months 
27.  Currently participating in an investigational drug or another device study that has not 
reached its primary endpoint. 
28.  Subject belongs to a vulnerable population or has any disorder that compromises 
his/her ability to give written informed consent and/or to comply with study 
procedures*“Corrected” refers to a 4% reduction in the BNP or NT-proBNP cutoff for 
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